Tracking the fate of bacteria-derived site-specific immunomodulators by positron emission tomography.

Autor: Kirby A; Department of Biology, University of Ottawa, Ottawa, ON, Canada; University of Ottawa Heart Institute, Ottawa, ON, Canada., Suchý M; University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Chemistry and Biomolecular Sciences, Ottawa, ON, Canada., Duan D; University of Ottawa Heart Institute, Ottawa, ON, Canada., Bazett M; Qu Biologics Inc., Vancouver, BC, Canada., Kalyan S; Qu Biologics Inc., Vancouver, BC, Canada; Department of Medicine, Division of Endocrinology, University of British Columbia, Vancouver, BC, Canada., Shuhendler AJ; Department of Biology, University of Ottawa, Ottawa, ON, Canada; University of Ottawa Heart Institute, Ottawa, ON, Canada; Department of Chemistry and Biomolecular Sciences, Ottawa, ON, Canada. Electronic address: adam.shuhendler@uottawa.ca.
Jazyk: angličtina
Zdroj: Nuclear medicine and biology [Nucl Med Biol] 2024 May-Jun; Vol. 132-133, pp. 108908. Date of Electronic Publication: 2024 Mar 28.
DOI: 10.1016/j.nucmedbio.2024.108908
Abstrakt: Introduction: Site-specific immunomodulators (SSIs) are a novel class of therapeutics made from inactivated bacterial species designed to regulate the innate immune system in targeted organs. QBECO is a gut-targeted SSI that is being advanced clinically to treat and/or prevent inflammatory bowel disease, cancer, and serious infections of the gastrointestinal (GI) tract and proximal organs, and QBKPN is a lung-targeted SSI that is in clinical development for the treatment and/or prevention of chronic inflammatory lung disease, lung cancers and respiratory tract infections. While these SSIs have demonstrated both safety and proof-of-concept in preclinical and clinical studies, detailed understanding of their trafficking and biodistribution is yet to be fully characterized.
Methods: QBECO and QBKPN were radiolabeled with [ 89 Zr] and injected subcutaneously into healthy mice. The mice underwent Positron Emission Tomography (PET) imaging every day for eight days to track biodistribution of the SSIs. Tissue from the site of injection was collected and immunohistologically probed for immune cell infiltration.
Results: Differential biodistribution of the two SSIs was seen, adhering to their site-specific targeting. QBKPN appeared to migrate from the site of injection (abdomen) to the cervical lymph nodes which are nearer to the respiratory tract and lungs. QBECO remained in the abdominal region, with lymphatic trafficking to the inguinal lymph nodes, which are nearer to GI-proximal tissues/organs. Immune infiltration at the site of injection comprised of neutrophils for both SSIs, and macrophages for only QBKPN.
Conclusion: Radiolabeling of SSIs allows for longitudinal in vivo imaging of biodistribution and trafficking. PET imaging revealed differential biodistribution of the SSIs based on the organotropism of the bacteria from which the SSI is derived. Trafficking from the site of injection to the targeted site is in part mediated via the lymphatics and involves macrophages and neutrophils.
Competing Interests: Declaration of competing interest SK is an employee of Qu Biologics.
(Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: